10 Year Financial Data of Valeant Pharmaceuticals International Inc (VRX)

78.17 (1y: +66%)

Market Cap	23.17 B	P/E(ttm)
Enterprise Value	33.37 B	P/B	6.51

VRX- NYSE (USA)
Valeant Pharmaceuticals International Inc

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$78.17

3 Severe Warning Signs 4 Medium Warning Signs

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	5.4	24.2	41.5
EBITDA Growth (%)	4.2	23.1	31
Free Cash Flow Growth (%)	0	0	-13.9
Book Value Growth (%)	9.6	14.2	-11.4

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	5.20	5.57	5.86	6.69	5.24	4.74	5.18	6.03	7.55	11.61	12.25	2.78	2.69	2.84	3.23	3.49
EBITDA per Share	1.16	1.89	2.25	2.11	1.80	1.42	2.08	0.74	2.80	3.49	4.07	0.90	1.01	0.85	0.71	1.50
Free Cashflow per Share	1.55	1.56	2.72	2.98	1.90	1.14	-1.31	1.26	0.89	1.56	1.84	0.50	0.79	0.33	-0.07	0.79
Earnings per Share ($)	-0.17	1.01	1.48	1.27	1.22	1.25	1.11	-1.06	0.49	-0.38	-0.43	-0.04	-0.07	0.02	-0.29	-0.09
Dividends Per Share	--	--	0.50	0.50	1.50	1.50	0.65	0.28	--	--	--	--	--	--	--	--
Book Value per Share	5.56	8.53	8.64	8.03	8.07	7.52	8.54	25.08	12.29	12.17	11.73	13.24	12.12	12.14	12.18	11.73
Month End Stock Price	21.49	16.53	23.73	21.16	13.46	9.45	13.96	28.29	46.69	59.77	75.02	53.69	44.79	55.27	59.77	75.02
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-3.10	3.90	6.50	15.90	15.10	16.60	13.00	-4.20	4.00	-3.10	-3.20	-1.20	-2.40	0.80	-9.60	-3.20
Return on Assets %	-1.40	2.60	4.10	9.40	11.00	12.30	8.50	-1.90	1.20	-0.60	-0.80	-0.40	-0.80	0.40	-2.00	-0.80
Return on Capital - Joel Greenblatt %	6.80	34.80	81.50	639	134	235	212	-33.80	38.10	8.20	44.40	30.40	44.00	12.40	-40.00	44.40
Debt to Equity	0.93	0.35	0.32	0.32	--	--	0.29	0.75	1.66	2.96	2.96	1.72	2.04	2.02	2.96	2.96

Gross Margin %	83.10	74.10	77.90	79.10	73.50	74.00	75.10	65.70	70.50	70.70	71.90	63.60	74.40	74.00	70.90	71.90
Operating Margin %	2.10	12.00	16.50	21.40	22.30	16.40	22.10	-9.30	12.20	2.20	11.00	7.20	10.60	3.30	-9.90	11.00
Net Margin %	-3.30	5.90	9.50	19.10	23.20	26.40	21.50	-17.60	6.50	-3.30	-2.60	-1.50	-2.60	0.90	-9.00	-2.60

Days Sales Outstanding	79.50	61.20	51.80	44.10	75.40	43.80	53.40	87.50	85.60	94.00	89.80	65.20	67.80	82.90	84.30	89.80
Days Inventory	220	175	158	129	132	110	148	207	178	187	154	109	169	165	169	154
Inventory Turnover	1.70	2.10	2.30	2.80	2.80	3.30	2.50	1.80	2.00	2.00	0.60	0.80	0.50	0.60	0.50	0.60

Debt to Revenue	1.00	0.54	0.47	0.39	--	--	0.48	3.13	2.70	3.11	9.94	8.17	9.21	8.63	11.17	9.94
COGS to Revenue	0.17	0.26	0.22	0.21	0.27	0.26	0.25	0.34	0.30	0.29	0.28	0.36	0.26	0.26	0.29	0.28
Inventory to Revenue	0.10	0.12	0.10	0.07	0.10	0.08	0.10	0.19	0.14	0.15	0.48	0.44	0.47	0.47	0.54	0.48
Interest Exp. to Revenue %	-4.04	-4.48	-3.16	-0.56	1.76	1.11	-2.96	-7.03	-13.35	-13.18	-14.39	-11.79	-12.14	-12.99	-15.41	-14.39

Asset Turnover	0.43	0.44	0.43	0.49	0.47	0.47	0.40	0.11	0.19	0.20	0.06	0.06	0.06	0.06	0.06	0.06
Buyback Ratio	44.30	-15.20	-3.00	-7.70	-5.70	--	-0.50	28.10	--	19.80	9.70	39.50	8.80	-68.10	12.10	9.70
Dividend Payout Ratio	--	--	0.90	0.39	1.23	1.20	0.58	--	--	--	--	--	--	--	--	--
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	824	887	936	1,070	843	757	820	1,181	2,463	3,547	3,759	856	820	884	986	1,068
Cost of Goods Sold	139	230	207	223	224	197	204	406	727	1,039	1,027	312	210	230	287	300
Gross Profit	684	657	729	847	619	560	616	775	1,737	2,508	2,732	544	610	654	700	768

Selling, General, &Admin. Expense	243	275	231	238	161	189	190	367	584	813	879	180	239	189	205	246
Research &Development	86.57	72.50	88.88	95.47	118	92.84	121	158	175	269	271	22.01	22.28	164	60.20	23.80
Earnings Before DDA	184	301	360	337	289	228	330	144	913	1,066	1,247	277	309	265	215	458

Depreciation, Depletion and Amortization	167	195	205	108	101	103	149	255	613	986	1,112	216	222	235	313	341

Operating Income	16.94	106	154	230	188	124	181	-110	300	79.69	135	61.50	86.81	29.46	-98.09	117
Interest Income/Expense	-33.26	-39.75	-29.54	-6.00	14.82	8.38	-24.30	-83.01	-329	-467	-520	-101	-99.59	-115	-152	-154
Net Income	-27.27	52.75	89.03	204	196	200	176	-208	160	-116	-131	-12.92	-21.61	7.65	-89.14	-27.53

Earnings per Share ($)	-0.17	1.01	1.48	1.27	1.22	1.25	1.11	-1.06	0.49	-0.38	-0.43	-0.04	-0.07	0.02	-0.29	-0.09
Total Shares Outstanding	159	159	160	160	161	160	159	196	326	305	306	308	305	312	305	306
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	133	39.34	446	834	438	319	124	400	170	921	414	332	395	258	921	414
Accounts Receivable	179	149	133	129	174	90.86	120	283	578	914	1,054	614	611	805	914	1,054
Inventory	84.06	110	89.47	78.78	80.75	59.56	82.77	230	355	531	510	374	389	418	531	510
Other Current Assets	15.76	16.40	16.82	15.05	14.68	21.40	23.92	107	254	412	393	213	235	233	412	393
Total Current Assets	412	315	685	1,058	707	490	351	1,020	1,358	2,777	2,370	1,532	1,630	1,714	2,777	2,370

Property, Plant and Equipment	174	187	200	212	238	148	104	282	414	463	453	427	409	450	463	453
Intangible Assets	1,150	1,399	1,188	798	731	821	1,436	9,374	11,257	14,450	14,393	11,539	11,846	11,835	14,450	14,393
Other Long Term Assets	186	112	115	108	106	164	177	119	113	260	271	122	134	147	260	271
Total Assets	1,923	2,012	2,188	2,175	1,782	1,624	2,067	10,795	13,142	17,950	17,486	13,620	14,020	14,146	17,950	17,486

Accounts Payable	173	124	150	215	318	159	216	553	695	1,331	1,255	708	772	812	1,331	1,255
Current Portion of Long-Term Debt	58.82	33.47	24.36	11.15	--	--	12.11	117	111	480	290	145	195	208	480	290
Other Current Liabilities	30.62	32.74	98.87	184	49.74	108	28.68	22.97	118	11.43	102	105	81.67	139	11.43	102
Total Current Liabilities	263	190	274	410	368	267	257	692	924	1,823	1,646	958	1,049	1,159	1,823	1,646

Long-Term Debt	764	442	413	401	--	--	380	3,574	6,540	10,535	10,327	6,851	7,356	7,423	10,535	10,327
Other Long-Term Liabilities	14.50	21.44	122	79.25	117	155	75.59	1,617	1,671	1,875	1,926	1,734	1,919	1,780	1,875	1,926
Total Liabilities	1,041	654	809	890	484	422	713	5,884	9,135	14,233	13,899	9,543	10,324	10,361	14,233	13,899

Common Stock	1,448	1,523	--	--	--	--	--	--	--	--	--	--	5,885	--	--	--
Retained Earnings	-608	-259	-249	-247	-278	-320	-246	-935	-2,030	-2,371	-2,424	-2,116	-2,246	-2,282	-2,371	-2,424
Additional Paid-In Capital	--	--	1,596	1,492	1,514	1,496	1,557	5,747	6,240	6,208	6,208	6,222	283	6,187	6,208	6,208
Total Equity	882	1,358	1,380	1,285	1,298	1,202	1,354	4,911	4,007	3,717	3,587	4,076	3,695	3,785	3,717	3,587
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-27.27	52.75	99.60	204	196	200	176	-208	160	-116	-131	-12.92	-21.61	7.65	-89.14	-27.53
Depreciation, Depletion and Amortization	167	195	205	108	101	103	149	255	613	986	1,112	216	222	235	313	341
Cash Flow from Others	142	29.71	193	210	44.55	-99.00	35.18	217	-95.69	-214	-237	-35.43	54.34	-76.13	-156	-58.57
Cash Flow from Operations	282	277	498	522	341	204	361	263	676	657	745	167	255	167	67.92	255

Investment for Property, Plant & Equipement	-36.92	-28.03	-63.81	-44.80	-35.09	-22.00	-569	-16.82	-386	-181	-183	-12.98	-14.30	-63.37	-90.48	-14.75
Cash Flow from Acquisitions	-25.74	-9.32	--	--	--	-102	-200	224	-2,464	-3,485	-3,450	-273	-454	-245	-2,513	-238
Cash Flow from Investing	-278	-42.26	31.78	-40.45	-15.05	-108	-743	229	-2,845	-2,966	-2,982	-218	-476	-297	-1,974	-235

Net Issuance of Stock	12.08	8.01	2.99	15.63	11.22	-29.84	0.87	-1.71	-639	-258	-186	-104	-170	5.21	10.80	-32.33
Net Issuance of Debt	60.44	-349	-40.89	-26.55	-418	--	350	196	2,771	3,471	2,697	346	504	95.34	2,525	-427
Cash Flow for Dividends	--	--	-79.78	-80.06	-322	-180	-147	-356	--	--	--	--	--	--	--	--
Other Financing	-0.00	6.30	-1.42	-1.27	-0.34	-0.18	-26.67	-51.31	-183	-156	-180	-32.17	-41.65	-108	26.69	-56.61
Cash Flow from Financing	72.52	-335	-119	-92.25	-729	-210	177	-213	1,948	3,057	2,331	210	292	-7.93	2,562	-516

Net Change in Cash	77.18	-98.94	411	389	-401	-116	-203	280	-230	752	83.26	166	64.79	-138	658	-502

Free Cash Flow	245	249	434	477	306	182	-208	246	291	475	562	154	240	103	-22.56	241
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
EV-to-EBITDA
EV-to-EBIT
Earnings Yield (Joel Greenblatt)
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

VRX Quarterly/Annuals Reports

VRX: 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL (0000930184) (Filer): (10-Q) - 2010-08-03
VRX: 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL (0000930184) (Filer): (10-Q) - 2010-05-03
VRX: 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL (0000930184) (Filer): (10-Q) - 2009-11-02
VRX: Quarterly report: (10-Q) - 2009-08-05
VRX: Quarterly report: (10-Q) - 2009-05-07

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

VRX Quarterly/Annuals Reports